Current Sites of Infections and Types of Microorganisms in Patient with Febrile Neutropenia in Hematological Wards – Single Center Study
DOI:
https://doi.org/10.3889/oamjms.2022.8446Keywords:
Neutropenia, Hematological malignancies, Leukemia, Lymphoma, Infection, Non-Hodgkin lymphomaAbstract
BACKGROUND: Febrile neutropenia occurs in more than 80% of patients with hematological malignances specially after chemotherapy cycles and an infectious source is identified in approximately 20–30%. Various bacterial, viral, and fungal pathogen contribute to the development of neutropenic fever and without prompt antibiotic therapy mortality rate can be as high as 70%.
AIM: The objective of the study was to document the current sites of infection in patients with febrile neutropenia in hematological ward in Baghdad Teaching Hospital, the microorganisms and antibiotic susceptibly in culture positive cases and mortality rate in 1 week and 4 weeks after episode of fever.
PATIENTS AND METHODS: One hundred cases of febrile neutropenia were evaluated in Hematological Ward of Baghdad Teaching Hospital from January 2019 to January 2020. Detailed history, physical examination, and laboratory investigations were conducted and statistical analysis of the results was done.
RESULTS: One hundred cases of febrile neutropenia, mean age of presentation was 41.56 ± 10.5 years. Acute myeloid leukemia (36%) and acute lymphocytic leukemia (26%) were the most common underlying hematological disorder, followed by Aplastic Anemia, Non-Hodgkin Lymphoma, and Hodgkin Lymphoma. Temperature ranged from 38°C to 39°C with mean temperature of 38.4°C and most of the patient presented with short duration of fever, 57% had absolute neutrophil count below 150 cells/μL with mean duration of neutropenia was 14.01 days. Respiratory tract was the most common site of infection (52%) followed by urinary tract (18%) and in 16% had no obvious focus of infection. Thirty percent of cases were culture Gram-positive and Gram-negative microorganism which were more common 62.9% which were generally sensitive to Aminoglycosides while Gram-positive microorganism constituted 29.6% of isolated bacteria and were generally sensitive to vancomycin. No mortality documented 1 and 4 weeks after fever.
CONCLUSION: We concluded that the most frequent sites of infection in patient with febrile neutropenia were respiratory tract followed by urinary tract infection, while 16% had undetermined source of infection. Thirty percent of patients had a positive blood culture with Escherichia coli being the most common infecting microorganism, Gram-negative microorganisms were more common than Gram-positive microorganism and fungal infection constituted about 6% of growth. Significant association was found between the fever and longer duration of neutropenia and the greater severity of neutropenia was observed. No mortality related to febrile neutropenia was documented.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):e56. https://doi.org/10.1093/cid/cir073 PMid:21258094 DOI: https://doi.org/10.1093/cid/cir073
Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American society of clinical oncology and infectious diseases society of America clinical practice guideline update. J Clin Oncol. 2018;36(14):1443-53. https://doi.org/10.1200/JCO.2017.77.6211 PMid:29461916 DOI: https://doi.org/10.1200/JCO.2017.77.6211
Rivera-Salgado D, Valverde-Muñoz K, Ávila-Agüero ML. Febrile neutropenia in cancer patients: Management in the emergency room. Rev Chilena Infectol. 2018;35(1):62-71. https://doi.org/10.4067/s0716-10182018000100062 PMid:29652973 DOI: https://doi.org/10.4067/s0716-10182018000100062
Hersh EM, Bodey GP, Nies BA, Freireich EJ. Causes of death in acute leukemia: A ten-year study of 414 patients from 1954-1963. JAMA. 1965;193:105. https://doi.org/10.1001/jama.1965.03090020019005 PMid:14304351 DOI: https://doi.org/10.1001/jama.1965.03090020019005
Zuckermann J, Moreira LB, Stoll P, Moreira LM, Kuchenbecker RS, Polanczyk CA. Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes. Ann Hematol. 2008;87(2):139-45. https://doi.org/10.1007/s00277-007-0390-7 PMid:17938926 DOI: https://doi.org/10.1007/s00277-007-0390-7
Pizzo PA. Management of fever in patients with cancer and treatmentinduced neutropenia. N Engl J Med. 1993;328(18):1323-32. https://doi.org/10.1056/NEJM199305063281808 PMid:8469254 DOI: https://doi.org/10.1056/NEJM199305063281808
Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, Wiernik PH. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med. 1972;77(5):707-14. https://doi.org/10.7326/0003-4819-77-5-707 PMid:4628214 DOI: https://doi.org/10.7326/0003-4819-77-5-707
Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med. 1985;145(9):1621-9. https://doi.org/10.1001/archinte.145.9.1621 PMid:3927867 DOI: https://doi.org/10.1001/archinte.145.9.1621
Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36(9):1103-10. https://doi.org/10.1086/374339 PMid:12715303 DOI: https://doi.org/10.1086/374339
Holland T, Fowler VG Jr., Shelburne SA 3rd. Invasive grampositive bacterial infection in cancer patients. Clin Infect Dis. 2014;59(Suppl 5):S331-4. https://doi.org/10.1093/cid/ciu598 PMid:25352626 DOI: https://doi.org/10.1093/cid/ciu598
Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer. 2005;103(6):1103-13. https://doi.org/10.1002/cncr.20890 PMid:15666328 DOI: https://doi.org/10.1002/cncr.20890
Raad I, Chaftari AM. Advances in prevention and management of central line-associated bloodstream infections in patients with cancer. Clin Infect Dis. 2014;59(Suppl 5):S340-3. https://doi.org/10.1093/cid/ciu670 PMid:25352628 DOI: https://doi.org/10.1093/cid/ciu670
Gudiol C, Bodro M, Simonetti A, Tubau F, González-Barca E, Cisnal M, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect. 2013;19(5):474-9. https://doi.org/10.1111/j.1469-0691.2012.03879.x PMid:22524597 DOI: https://doi.org/10.1111/j.1469-0691.2012.03879.x
Montassier E, Batard E, Gastinne T, Potel G, de La Cochetière MF. Recent changes in bacteremia in patients with cancer: A systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 2013;32(7):841-50. https://doi.org/10.1007/s10096-013-1819-7 PMid:23354675 DOI: https://doi.org/10.1007/s10096-013-1819-7
Trecarichi EM, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: Current epidemiology and clinical impact. Curr Opin Infect Dis. 2014;27(2):200-10. https://doi.org/10.1097/QCO.0000000000000038 PMid:24573013 DOI: https://doi.org/10.1097/QCO.0000000000000038
Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014;68(4):321-31. https://doi.org/10.1016/j.jinf.2013.12.006 PMid:24370562
Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol. 2008;26(35):5684-8. https://doi.org/10.1200/JCO.2008.16.4681 PMid:18955453 DOI: https://doi.org/10.1200/JCO.2008.16.4681
Cho SY, Choi HY. Opportunistic fungal infection among cancer patients. A ten-year autopsy study. Am J Clin Pathol. 1979;72(4):617-21. https://doi.org/10.1093/ajcp/72.4.617 PMid:495566 DOI: https://doi.org/10.1093/ajcp/72.4.617
Walsh TJ, Gamaletsou MN. Treatment of fungal disease in the setting of neutropenia. Hematol Am Soc Hematol Educ Program. 2013;2013:423-7. https://doi.org/10.1182/asheducation-2013.1.423 PMid:24319214 DOI: https://doi.org/10.1182/asheducation-2013.1.423
Saral R, Ambinder RF, Burns WH, Angelopulos CM, Griffin DE, Burke PJ, et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, doubleblind, placebo-controlled study. Ann Intern Med 1983;99:773-6. https://doi.org/10.7326/0003-4819-99-6-773 PMid:6359995 DOI: https://doi.org/10.7326/0003-4819-99-6-773
Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med. 1981;305(2):63-7. PMid:6264292 DOI: https://doi.org/10.1056/NEJM198107093050202
Lee HS, Park JY, Shin SH, Kim SB, Lee JS, Lee A, et al. Herpesviridae viral infections after chemotherapy without antiviral prophylaxis in patients with malignant lymphoma: Incidence and risk factors. Am J Clin Oncol. 2012;35(2):146-50. https://doi.org/10.1097/COC.0b013e318209aa41 PMid:21325936 DOI: https://doi.org/10.1097/COC.0b013e318209aa41
Mikulska M, Del Bono V, Gandolfo N, Dini S, Dominietto A, Di Grazia C, et al. Epidemiology of viral respiratory tract infections in an outpatient haematology facility. Ann Hematol. 2014;93(4):669-76. https://doi.org/10.1007/s00277-013-1912-0 PMid:24097084 DOI: https://doi.org/10.1007/s00277-013-1912-0
Mori Y, Miyamoto T, Kato K, Kamezaki K, Kuriyama T, Oku S, et al. Different risk factors related to adenovirus-or BK virus-associated hemorrhagic cystitis following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(3):458-65. https://doi.org/10.1016/j.bbmt.2011.07.025 PMid:21810401 DOI: https://doi.org/10.1016/j.bbmt.2011.07.025
Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of antituberculosis drug resistance 2002-07: An updated analysis of the global project on anti-tuberculosis drug resistance surveillance. Lancet. 2009;373(9678):1861-73. https://doi.org/10.1016/S0140-6736(09)60331-7 PMid:19375159 DOI: https://doi.org/10.1016/S0140-6736(09)60331-7
Bodey G. Management of febrile neutropenia: Current strategies. Clin Infect Dis. 2005;40(Suppl 4):S237-8. DOI: https://doi.org/10.1086/427332
Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock. Crit Care Med. 2008;36(1):296-327. https://doi.org/10.1097/01.CCM.0000298158.12101.41 PMid:18158437 DOI: https://doi.org/10.1097/01.CCM.0000298158.12101.41
Link H, Böhme A, Cornely OA, Höffken K, Kellner O, Kern WV, et al. Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the infectious diseases working party (AGIHO) of the German society of hematology and oncology (DGHO), study group interventional therapy of unexplained fever, arbeitsgemeinschaft supportivmassnahmen in der onkologie (ASO) of the deutsche krebsgesellschaft (DKG-German cancer society). Ann Hematol. 2003;82(Suppl 2):S105-17. https://doi.org/10.1007/s00277-003-0764-4 PMid:13680173 DOI: https://doi.org/10.1007/s00277-003-0764-4
Bell MS, Scullen P, McParlan D. Neutropenic Sepsis Guidelines. Belfast: Northern Ireland Cancer Network; 2010. p. 1-11.
Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(6):794-810. https://doi.org/10.1200/JCO.2012.45.8661 PMid:23319691 DOI: https://doi.org/10.1200/JCO.2012.45.8661
Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971;284(19):1061-5. PMid:4994878 DOI: https://doi.org/10.1056/NEJM197105132841904
McKenzie H, Hayes L, White K, Cox K, Fethney J, Boughton M, et al. Chemotherapy outpatients’ unplanned presentations to hospital: A retrospective study. Support Care Cancer. 2011;19(7):963-9. https://doi.org/10.1007/s00520-010-0913-y PMid:20499108 DOI: https://doi.org/10.1007/s00520-010-0913-y
Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975;135(5):715-9. PMid:1052668 DOI: https://doi.org/10.1001/archinte.135.5.715
Sepkowitz KA. Treatment of patients with hematologic neoplasm, fever, and neutropenia. Clin Infect Dis 2005;40(Suppl 4):S253-6. https://doi.org/10.1086/427330 PMid:15768331 DOI: https://doi.org/10.1086/427330
Kern WV, Marchetti O, Drgona L, Akan H, Aoun M, Akova M, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: A double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy—EORTC infectious diseases group trial XV. J Clin Oncol. 2013;31(9):1149. https://doi.org/10.1200/JCO.2012.45.8109 PMid:23358983 DOI: https://doi.org/10.1200/JCO.2012.45.8109
Cornely OA, Wicke T, Seifert H, Bethe U, Schwonzen M, Reichert D, et al. Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: A randomized controlled multicenter trial in patients with febrile neutropenia. Int J Hematol. 2004;79(1):74-8. https://doi.org/10.1007/BF02983537 PMid:14979482 DOI: https://doi.org/10.1007/BF02983537
Siddiqui B, Azmat R, Tikmani S, Rafi S, Syed B, Khan MT, et al. Frequency of bloodstream infections in febrile neutropenia patients, experience from a developing country. Ann Med Surg. 2018;34:71-4. https://doi.org/10.1016/j.amsu.2018.09.004 PMid:30258624 DOI: https://doi.org/10.1016/j.amsu.2018.09.004
Yadegarynia D, Fatemi A, Mahdizadeh M, Movahhed RK, Alizadeh MA. Current spectrum of bacterial infections in patients with nosocomial fever and neutropenia. Caspian J Intern Med. 2013;4(3):698-701. PMid:24009963
Hassan BA, Yusoff ZB, Othman SB. A Close Look at Neutropenia among Cancer Patients Risk Factor and Management, Updates on Cancer Treatment, Leticia B. A. Rangel and Ian Victor Silva. London: IntechOpen; 2015. DOI: https://doi.org/10.5772/60794
Görük M, Dal MS, Dal T, Karakus A, Tekin R, Özcan N, et al. Evaluation of febrile neutropenic patients hospitalized in a hematology clinic. Asian Pac J Trop Biomed. 2015;52(4):1051-4. https://doi.org/10.5152/TurkPediatriArs.2017.5312 PMid:29483801 DOI: https://doi.org/10.1016/j.apjtb.2015.09.014
Diaz B. Neutropenia and Avoiding Infection in Patients With Acute Myeloid Leukemia; AJMC Managed Markets Network; May 05; 2016. Available from: https://www.ajmc.com/newsroom/neutropenia-and-avoiding-infection-in-patients-with-acutemyeloid-leukemia [Last accessed on 2021 Sep 23]
Karimi F, Ashrafi F, Moghaddas A, Derakhshandeh A. Management of febrile neutropenia: A description of clinical and microbiological findings by focusing on risk factors and pitfalls. J Res Pharm Pract. 2018;7(3):147-56. https://doi.org/10.4103/jrpp.JRPP_18_16 PMid:30211240 DOI: https://doi.org/10.4103/jrpp.JRPP_18_16
Hosiriluck N, Klomjit S, Rassameehiran S, Sutamtewagul G, Tijani L, Radhi S. Prognostic factors for mortality with febrile neutropenia in hospitalized patients. Southwest Respir Crit Care Chronicles. 2015;3(9):3. https://doi.org/10.12746/swrccc.v3i9.188 DOI: https://doi.org/10.12746/swrccc.v3i9.188
Carpenter SM, Vianello F, Poznansky MC. Febrile Neutropenia: Harrison’s Manual of Oncology. 2nd ed. New York: McGraw Hill Education; 2013.
Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34(6):730-51. https://doi.org/10.1086/339215 PMid:11850858 DOI: https://doi.org/10.1086/339215
Lyman GH, Rolston KV. How we treat febrile neutropenia in patients receiving cancer chemo-therapy. J Oncol Pract. 2010;6(3):149-52. https://doi.org/10.1200/JOP.091092 PMid:20808559 DOI: https://doi.org/10.1200/JOP.091092
Meidani M, Rostami M, Moulaee S. Blood culture in neutropenic patients with fever. Int J Prev Med. 2012;3(2):141-2. PMid:22347613
Bouafia N, Ammar A, Ezzi O, Ben Chiekh A, Mahjoub M, Bannour W, et al. Prospective surveillance of hospital associated infections epidemiology in a haematology-oncology department. Int J Infect Control. 2019;15(1):268. DOI: https://doi.org/10.3396/ijic.v15i1.002.19
Wringley J, Ajithkumar TV. Oncologist Emergencies. Edinburgh: Mosby Elsevier; 2011. p. 328-47. DOI: https://doi.org/10.1016/B978-0-7234-3458-0.00028-2
De Bock R, Cometta A, Kern W. Incidence of single agent Gram-negative bacteremias (SAGNB) in neutropenic cancer patients (NCP) in EORTC-IATG trials of empirical therapy for febrile neutropenia [abstract L-773], Program and abstracts of the 41st Inter science Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology; 2001. p. 445.
Mandal PK, Maji SK, Dolai TK. Micro-organisms Associated with Febrile Neutropenia in Patients with Haematological Malignancies in a Tertiary Care Hospital in Eastern India. Indian J Hematol Blood Transfus. 2015;31:46. https://doi.org/10.1007/s12288-014-0393-1 DOI: https://doi.org/10.1007/s12288-014-0393-1
Sönmez A, Eksi F, Pehlivan M, Sahin HH. Investigating the presence of fungal agents in febrile neutropenic patients using different microbiological, serological, and molecular methods. Bosn J Basic Med Sci. 2015;15(3):40-7. https://doi.org/10.17305/bjbms.2015.409 PMid:26295293 DOI: https://doi.org/10.17305/bjbms.2015.409
Gaytán-Martínez J, Mateos-Garcia E, Sanchez-Cortes E, Gonzalez-Llaven J, Casanova-Cardiel LJ, Fuentes-Allen JL. Microbiological findings in febrile neutropenia. Arch Med Res. 2000;31(4):388-92. https://doi.org/10.1016/s0188-4409(00)00080-1 PMid:11068081 DOI: https://doi.org/10.1016/S0188-4409(00)00080-1
Herbers AH, de Haan AF, van der Velden WJ, Donnelly JP, Blijlevens NM. Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2014;16(2):279-85. http://dx.doi.org/10.1111/tid.12195 PMid:24621081 DOI: https://doi.org/10.1111/tid.12195
Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C, et al. Fourth European Conference on Infections in Leukemia Group ajvoEEIELN, Esgich/Escmid. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014;68(4):321-31. http://dx.doi.org/10.1016/j.jinf.2013.12.006 PMid:24370562 DOI: https://doi.org/10.1016/j.jinf.2013.12.006
Sood P, Seth T, Kapil A, Sharma V, Dayama A, Sharma S, et al. Emergence of multidrug resistant acinetobacter blood stream infections in febrile neutropenia patients with haematological cancers and bone marrow failure syndromes. J Indian Med Assoc. 2012;110(7):439-44. PMid:23520666
Jeddi R, Achour M, Ben Amor R, Aissaoui L, Bouterâa W, Kacem K, et al. Factors associated with severe sepsis: Prospective study of 94 neutropenic febrile episodes. Hematology. 2010;15:28-32. DOI: https://doi.org/10.1179/102453310X12583347009577
Aubron C, Poirel L, Fortineau N, Nicolas P, Collet L, Nordmann P. Nosocomial spread of Pseudomonas aeruginosa isolates expressing the metallo-beta-lactamase VIM-2 in a hematology unit of a French hospital. Microb Drug Resist. 2005;11(3):254-9. http://doi.org/10.1089/mdr.2005.11.254 PMid:16201928 DOI: https://doi.org/10.1089/mdr.2005.11.254
Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: Epidemiology, microbiology, and risk stratification. Clin Infect Dis. 2005;40(Suppl 4):S240-5. https://doi.org/10.1086/427329 DOI: https://doi.org/10.1086/427329
PMid:15768329
Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: Summary of the 2011 4th European conference on infections in leukemia. Haematologica. 2013;98(12):1826-35. https://doi.org/10.3324/haematol.2013.091025 PMid:24323983 DOI: https://doi.org/10.3324/haematol.2013.091025
Heidenreich D, Kreil S, Nolte F, Reinwald M, Hofmann WK, Klein SA. Allogeneic hematopoietic cell transplantation without fluconazole and fluoroquinolone prophylaxis. Ann Hematol. 2016;95(2):287-93. PMid:26494235 DOI: https://doi.org/10.1007/s00277-015-2535-4
Zahid KF, Hafeez H, Afzal A. Bacterial spectrum and susceptibility patterns of pathogens in adult febrile neutropenic patients: A comparison between two time periods. J Ayub Med Coll Abbottabad. 2009;21(4):146-9. PMid:21067049
Wareham DW, Bean DC, Khanna P, Hennessy EM, Krahe D, Ely A, et al. Bloodstream infection due to Acinetobacter spp: Epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis. 2008;27(7):607-12. https://doi.org/10.1007/s10096-008-0473-y PMid:18283503 DOI: https://doi.org/10.1007/s10096-008-0473-y
Kontoyiannis D, Lewis R, Marr K. The burden of bacterial and viral infections in hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2009;15(Suppl 1):128-33. https://doi.org/10.1016/j.bbmt.2008.10.005 PMid:19147091 DOI: https://doi.org/10.1016/j.bbmt.2008.10.005
Kjellander C, Bjorkholm M, Cherif H, Kalin M, Giske CG. Hematological: Low all-cause mortality and low occurrence of antimicrobial resistance in hematological patients with bacteremia receiving no antibacterial prophylaxis: A singlecenter study. Eur J Haematol. 2012;88(5):422-30. https://doi.org/10.1111/j.1600-0609.2012.01768 PMid:22335785 DOI: https://doi.org/10.1111/j.1600-0609.2012.01768.x
Krishnamani K, Gandhi LV, Raghunadharao D. Epedimiologic, clinical profile and factors affecting the outcome in febrile neutropenia. South Asian J Cancer 2017;6(1):25-7. https://doi.org/10.4103/2278-330X.202565 PMid:28413792 DOI: https://doi.org/10.4103/2278-330X.202565
Velasco E, Byington R, Martins CA, Schirmer M, Dias LM, Gonçalves VM. Prospective evaluation of the epidemiology, microbiology and outcome of bloodstream infections in hematologic patients in a single cancer center. Eur J Clin Microbiol Infect Dis. 2003;22(3):137-43. https://doi.org/10.1007/s10096-003-0894-6 PMid:12649710 DOI: https://doi.org/10.1007/s10096-003-0894-6
Kuderer N, Dale D, Crawford J, Cosler L, Lyman G. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258-66. https://doi.org/10.1002/cncr.21847 PMid:16575919 DOI: https://doi.org/10.1002/cncr.21847
Nordvig J, Aagaard T, Daugaard G, Brown P, Sengeløv H, Lundgren J, et al. Febrile neutropenia and long-term risk of infection among patients treated with chemotherapy for malignant diseases. Open Forum Infect Dis. 2018;5(10):ofy255. https://doi.org/10.1093/ofid/ofy255 PMid:30377628 DOI: https://doi.org/10.1093/ofid/ofy255
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Alaadin Naji, Saman SarKo, Sama Atta (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
